RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Cardiovascular safety during and after use of phentermine and topiramate
Ritchey, M. E., Harding, A., Hunter, S., Peterson, C., Sager, P. T., Kowey, P. R., Nguyen, L., Thomas, S., Cainzos-Achirica, M., Rothman, K. J., Andrews, E. B., & Anthony, M. S. (2019). Cardiovascular safety during and after use of phentermine and topiramate. The Journal of Clinical Endocrinology and Metabolism, 104(2), 513-522. https://doi.org/10.1210/jc.2018-01010
Context: Increases in heart rate were seen during the clinical program for fixed-dose combination phentermine (PHEN) and topiramate (TPM), an oral medication indicated for weight management; however, the effect on cardiovascular (CV) outcomes is uncertain.
Objective: The aim of the present study was to determine the extent to which the rates of major adverse CV events (MACE) in patients using PHEN and TPM (including fixed dose) differed from the MACE rates during unexposed periods.
Design: Retrospective cohort study.
Setting: MarketScan, US insurance billing data.
Patients or Other Participants: Patients aged >18 years with ≥6 months of continuous enrollment in the database before taking PHEN and/or TPM or after stopping these medications.
Interventions: PHEN and TPM, taken separately and together (including fixed dose).
Main Outcome Measures: MACE, a composite of hospitalization for acute myocardial infarction and stroke and in-hospital CV death.
Results: Because the outcomes are rare and the duration of medication use was brief, few events occurred. The MACE rates among current users of PHEN/TPM, fixed-dose PHEN/TPM, and PHEN were lower than those among unexposed former users. In contrast, the rate of MACE among current users of TPM was greater than among unexposed former users [incidence rate ratio: PHEN/TPM, 0.57; 95% CI, 0.19 to 1.78; fixed-PHEN/TPM, 0.24; 95% CI, 0.03 to 1.70; PHEN, 0.56; 95% CI, 0.34 to 0.91; TPM, 1.58; 95% CI, 1.33 to 1.87).
Conclusions: Overall, the data indicated no increased risk of MACE for current PHEN/TPM users; however, the 95% CIs for the PHEN/TPM groups were broad, indicating that the data were compatible with a wide range of possible values.
